On February 4, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0)("Rakovina" or the "Company"), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, reported a corporate update following the participation of its President and Chief Scientific Officer, Prof. Mads Daugaard, at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The summit, which gathered global academic and industry leaders from institutions including Dana-Farber, MD Anderson, Merck, and Roche, served as a critical forum for discussing the future of DDR therapeutics. Prof. Daugaard presented Rakovina’s AI-driven strategy to develop brain-penetrant inhibitors and participated in expert panels on translational strategy and investment alignment.

Validating the Strategy: Solving the "Brain Penetration" Gap

A focal point of the summit was the clinical landscape of ATR inhibitors, specifically considering recent Phase 3 data in non-small cell lung cancer (NSCLC)

Rakovina’s presentation highlighted a distinct competitive advantage: unlike current clinical-stage candidates, Rakovina’s lead kt-5000 series is designed to be dual-targeting (ATR + mTOR) and brain-penetrant.

"The consensus from the summit is that the field is hungry for a brain-penetrant ATR inhibitor," said Prof. Mads Daugaard, Chief Scientific Officer of Rakovina Therapeutics. "While other programs face challenges with patient stratification and blood-brain barrier penetration, our data supports a different path: positioning ATR inhibition in a PTEN-deficient context with added mTOR blockade to shut down resistance pathways. The feedback we received from clinical thought leaders was clear, we are addressing the exact limitations that have held this drug class back."

Interest in Novel ADC Payloads

In addition to its small-molecule pipeline, the Company received inbound interest regarding its kt-3000 series as potential payloads for Antibody-Drug Conjugates (ADCs). With major pharmaceutical companies actively seeking novel payloads to overcome resistance to current ADC therapies, Rakovina intends to prioritize proof-of-concept studies to further unlock this partnership value.

"Our participation in Boston transformed our standing from a quiet innovator to a recognized problem-solver in the DDR space," added Prof. Daugaard. "We have confirmed that our scientific rationale is sound, our targets are high-value, and our AI-designed molecules are doing what the competition cannot: reach the brain."

(Press release, Rakovina Therapeutics, FEB 4, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-reports-strong-industry-validation-and-emerging-collaborations-following-9th-annual-ddr-inhibitors-summit [SID1234662476])

On February 4, 2026 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, reported that the Company will participate in two upcoming healthcare conferences in February 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On Thursday February 12, 2026, at 2:30 PM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY.

On Thursday February 26, 2026, at 8:40 AM EST, Aclaris’ President and Chief Operating Officer Hugh Davis, Ph.D. will provide a corporate presentation during the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference.

A live and archived webcast of both events will be accessible on the Events page of View Source The webcasts will be available on the Aclaris website for at least 30 days.

(Press release, Aclaris Therapeutics, FEB 4, 2026, View Source [SID1234662462])

On February 4, 2026 Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, reported that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11 at 9:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to a live webcast of this event, or access an archived webcast, please visit: View Source Following the live webcast, a replay will be available on the company’s website for at least 14 days.

(Press release, Revolution Medicines, FEB 4, 2026, View Source [SID1234662477])

On February 4, 2026 C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, reported that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fireside Chat Details:
Date: Wednesday, February 11, 2026
Time: 11:30 AM ET

A live webcast will be available on the Investors section of the company’s website at www.c4therapeutics.com. An archived replay of the webcast will be available for approximately 90 days following the event.

(Press release, C4 Therapeutics, FEB 4, 2026, View Source [SID1234662463])

On February 4, 2026 Tempest Therapeutics, Inc. (Nasdaq: TPST) ("Tempest"), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeutic assets, reported the closing of a previously announced transaction pursuant to which Tempest acquired certain dual-targeting chimeric antigen receptor (CAR)-T programs and obtained financing support from Factor Bioscience Inc. and its affiliates (collectively, "Factor") in an all-stock transaction resulting in a diverse portfolio including clinical-stage product candidates and an extended runway with multiple potential near-term milestones (the "Transaction").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am excited to join the Tempest team and to have the opportunity to develop this innovative pipeline of potential therapies to treat a range of solid tumors and hematologic malignancies," said Dr. Matt Angel, President and Chief Executive Officer of Tempest. "I look forward to advancing the company’s vision of bringing important therapies to patients."

"The Board is pleased to announce the closing of this transaction, which not only provides increased financial stability for Tempest, but also the opportunity for potentially significant milestones over the next 12-18 months from both the legacy small molecule programs and the new cell therapy assets," said Stephen Brady, Chair of the Board.

"As Tempest moves into this next phase, we would like to thank Geoff Nichol and Mike Raab." Mr. Brady continued. "We are grateful for Geoff’s support, engagement and inquisitive mind since he joined the Board in 2021, and wish him continued success in his endeavors. Mike Raab has been our Chair since 2018, during which time he provided clear leadership, thoughtful perspectives, and significant contributions to Tempest throughout his tenure. We are thrilled that Mike will continue to serve on the Board, bringing the ongoing benefit of his experience and guidance to the company."

Key Takeaways:

Amezalpat (TPST-1120) remains Phase 3 ready in first-line liver cancer ("HCC"), supported by global regulatory agreement and positive randomized Phase 2 data. Tempest plans to pursue business development discussions to advance pivotal development.
TPST-2003: new dual-targeting CD19/BCMA CAR-T asset
Phase 1 complete in patients with relapsed/refractory multiple myeloma ("rrMM"), with data expected in 2026 and a biologics license application ("BLA") in China planned for 2027
Phase 1 currently enrolling patients with POEMS syndrome, with data expected in 2027 and a BLA in China planned for 2028
Tempest has global rights to TPST-2003 outside of China, India, Turkey and Russia, and plans to pursue a potential registrational study in rrMM in the U.S. starting in 2027
Pivotal data from the Chinese study expected to validate probability of success for the program, and rights include the right to reference data generated in support of the planned China BLA
All development activities in China to be funded by strategic partner
Tempest expects a Phase 2 study of TPST-1495 in familial adenomatous polyposis ("FAP") to enroll the first patient in Q1’26 and to be funded by the National Cancer Institute and operationalized by the Cancer Prevention Clinical Trials Network.
Plan to continue the development of additional new preclinical and research-stage pipeline programs:
TPST-2206: dual-targeting CD70/CD70 CAR-T for renal cell carcinoma
TPST-3003: allogeneic dual-targeting CD19/BCMA
TPST-3206: allogeneic dual-targeting CD70/CD70
Existing cash and an investment commitment from Factor is expected to provide a runway to mid-2027 and potentially through key data milestones.
Combined Pipeline

Tempest Therapeutics Combined Pipeline
Advisors

MTS Health Partners, L.P. served as financial advisor to Tempest, and Cooley LLP served as legal advisor. In addition, MTS Securities, LLC (an affiliate of MTS Health Partners, L.P.) provided an opinion to the board of directors of Tempest regarding the fairness of the purchase price to be paid by Tempest to Factor in connection with the Transaction, subject to the qualifications and limitations set forth therein. Morse, Barnes-Brown & Pendleton, P.C. served as legal advisor to Factor.

(Press release, Tempest Therapeutics, FEB 4, 2026, View Source [SID1234662478])